Pablo Mora, MD

Video

How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?

How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?

Video

From a clinical perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide?

From a clinical perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide?

Video

Why is the combination of basal insulin and a GLP-1 RA logical from the standpoint of mechanistic complementarity?

Why is the combination of basal insulin and a GLP-1 RA logical from the standpoint of mechanistic complementarity?

Video

What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact pan-glycemic--FPG and PPG--control and other target goals and risk factors?

What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this strategy impact pan-glycemic—FPG and PPG—control and other metabolic target goals and risk factors?

Video

What incretin-targeted therapies are available to modulate the incretin hormones and what are the clinical differences among the available options?

What incretin-targeted therapies are available to modulate the incretin hormones and what are the clinical differences among the available options?

Video

What is the underlying physiology that explains the role of incretins in the disease processes leading to T2D?

What is the underlying physiology that explains the role of incretins in the disease processes leading to T2D?